Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
BridgeBio heart drug approved by FDA, setting up battle with …
1 天前 · Notably, the drug is approved to prevent hospitalization or death resulting from heart complications of transthyretin amyloidosis with cardiomyopathy. Investors had been skeptical BridgeBio would earn such a distinction from regulators, leading to doubts about Attruby’s commercial prospects.. BridgeBio priced Attruby at just under $19,000 for a 28-day supply, translating to an annual list ...
Novartis wagers more than $1B on gene therapies for the nervous …
2 天之前 · Novartis is betting the gene therapy technologies developed by Kate Therapeutics, a biotechnology startup founded four years ago, can lead to treatments for an array of neuromuscular diseases. The Swiss pharmaceutical giant said Thursday it has acquired Kate, in a transaction that could ultimately be worth as much as $1.1 billion.
Pharma News | BioPharma Dive
4 天之前 · Halozyme bids for Evotec; BeiGene gets a new name. The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first Lyfgenia revenue and Leerink built up its M&A team. By BioPharma Dive staff • Nov. 15, 2024.
Biotech M&A has plateaued. Track the deals that are happening …
2024年11月13日 · The expanding world of RNA therapies. Medicines from Alnylam, Ionis, Moderna and others have proven the power of RNA in medicines. A growing field of startups is advancing alongside them. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or ...
Clinical Trial News - BioPharma Dive
5 天之前 · Roche weighs whether speedy approval path is open for latest Alzheimer’s drug. In an investor presentation, executives hinted at the possibility of seeking an accelerated approval of trontinemab if it can significantly lower levels of amyloid …
Biotech News - BioPharma Dive
3 天之前 · Surviving in biotech’s new normal: 5 tips from industry VCs and CEOs. At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending and maintaining lines of sight to the clinic. By Ned Pagliarulo , Delilah Alvarado • Nov. 15, 2024. News roundup.
FDA endorses speedy approval path for Regenxbio Duchenne …
5 天之前 · Dive Brief: Regenxbio has aligned with the Food and Drug Administration on an abbreviated approval path for an experimental gene therapy the company is developing for Duchenne muscular dystrophy.; Following discussions with the agency, an existing Phase 1/2 study has been expanded into a pivotal trial that can …
Deals - BioPharma Dive
2024年10月29日 · GSK to pay $300M to license drug it sees as potential lupus treatment. The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease. By Ned Pagliarulo • Oct. 29, 2024.
‘Find any advantage’: 3 biotech leaders on driving R&D success
2024年11月15日 · But advantages don’t just come from in-the-weeds genetic analyses, Flynn said. “Find any advantage into your approach, your mechanism, your speed of delivery of clinical data, or actual clinical execution,” he said. “It could be something as seemingly simple as [chemistry, manufacturing and controls] readiness for later stage studies or ...